Drug recall · April 27, 2022
Rifampin for Injection recall
Why: Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rifampin for Injection, USP, 600 mg/vial, One Vial per carton, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., NDC 67457-445-60
- Lots / codes
Lot #: 7008990, exp. date Dec-2022; 7009025, exp. date Feb-2023; 7009085, 7009086, exp. date Apr-2023
- Quantity
- 33,893 vials
- Company
- Mylan Pharmaceuticals Inc, Morgantown, WV
- Distribution
- Nationwide in the USA
- Initiated
- April 7, 2022 · Voluntary: Firm initiated
- Classified
- April 15, 2022
- Reported
- April 27, 2022
- Ended
- May 23, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rifampin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.